Showing 7 posts of 7 posts found.

Cabometyx scores Japanese approval for unresectable hepatocellular carcinoma patients following systemic therapy

November 30, 2020
Sales and Marketing Cabometyx, Japan, Takeda

The Japanese Ministry of Health, Labor and Welfare has awarded approval to Takeda for Cabometyx (cabozantinib) as a treatment for …


Ipsen’s Cabometyx gains European approval in hepatocellular carcinoma

November 16, 2018
Medical Communications, Sales and Marketing Cabometyx, carcinoma, ipsen, pharma. European Commission

Ipsen’s Cabometyx has received approval from the European Commission for Cabometyx (cabozantinib) as a monotherapy for the treatment of hepatocellular …


Ipsen reveals positive Phase 3 data of Cabometyx in liver cancer

July 5, 2018
Research and Development Cabometyx, Cancer, ipsen, liver cancer, pharma

French pharmaceutical company Ipsen has announced that The New England Journal of Medicine has published the results of a Phase …

Ipsen receives European first-line approval for Cabometyx

May 17, 2018
Sales and Marketing Cabometyx, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen has revealed that it has received approval for the use of Cabometyx for first-line use in patients with advanced …


Ipsen ends P3 trial on liver cancer early due to strong data

January 18, 2018
Research and Development Cabometyx, Exelixis, biotech, drugs, ipsen, pharma, pharmaceutical

Ipsen and Exelixis, partners in developing Cabometyx (cabozantinib), have revealed that they have cut short a Phase 3 trial into …

Ipsen secures NICE approval for multi-targeting kidney cancer therapy

July 11, 2017
Manufacturing and Production, Sales and Marketing Cabometyx, Kidney cancer, NICE

Ipsen has announced that its therapy Cabometyx (cabozantinib) has been given approval by NICE for the treatment of advanced renal …


Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016
Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …

Latest content